Gilead Covid-19 drug remdesivir benefited from $6.5B in NIH-funded basic research, study finds
Research on the drug’s molecular target dates back to the 1950s. A spokesperson for Gilead noted that the company anticipates potentially investing more than $1 billion on the drug this year alone.
